C J Fleming1, A M Bryden, A Evans, R S Dawe, S H Ibbotson. 1. Departments of Dermatology and Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. colin.j.fleming@tuht.scot.nhs.uk
Abstract
BACKGROUND: Lentigo maligna (LM) is an in situ form of malignant melanoma, and surgical excision is often unsatisfactory. Imiquimod cream is an immune response modifier and induces a predominantly T-helper 1 type response. OBJECTIVES: Assessment of histological and clinical response of surgically resectable LM after treatment with 5% imiquimod cream. METHODS: Six patients with LM were treated with 5% imiquimod cream daily for 6 weeks. The whole site of the original lesion was then excised. Clinical and histological and appearances were measured using clinical response and histological grading scores. RESULTS: Complete or almost complete clearance of pigmentation with minimal residual histological evidence of LM was observed in four patients, one patient showed no clinical or histological improvement, and the remaining patient had almost no residual pigmentation clinically after treatment yet histopathological changes remained as severe as before treatment. CONCLUSIONS: Topical imiquimod cream merits further investigation as a new therapy for LM.
BACKGROUND:Lentigo maligna (LM) is an in situ form of malignant melanoma, and surgical excision is often unsatisfactory. Imiquimod cream is an immune response modifier and induces a predominantly T-helper 1 type response. OBJECTIVES: Assessment of histological and clinical response of surgically resectable LM after treatment with 5% imiquimod cream. METHODS: Six patients with LM were treated with 5% imiquimod cream daily for 6 weeks. The whole site of the original lesion was then excised. Clinical and histological and appearances were measured using clinical response and histological grading scores. RESULTS: Complete or almost complete clearance of pigmentation with minimal residual histological evidence of LM was observed in four patients, one patient showed no clinical or histological improvement, and the remaining patient had almost no residual pigmentation clinically after treatment yet histopathological changes remained as severe as before treatment. CONCLUSIONS: Topical imiquimod cream merits further investigation as a new therapy for LM.
Authors: Tomoko Hayashi; Michael Chan; John T Norton; Christina C N Wu; Shiyin Yao; Howard B Cottam; Rommel I Tawatao; Maripat Corr; Dennis A Carson; Gregory A Daniels Journal: Melanoma Res Date: 2011-02 Impact factor: 3.599
Authors: Eric M Bachelder; Tristan T Beaudette; Kyle E Broaders; Jean M J Fréchet; Mark T Albrecht; Alfred J Mateczun; Kristy M Ainslie; John T Pesce; Andrea M Keane-Myers Journal: Mol Pharm Date: 2010-06-07 Impact factor: 4.939
Authors: Tomoko Hayashi; Shiyin Yao; Brian Crain; Michael Chan; Rommel I Tawatao; Christine Gray; Linda Vuong; Fitzgerald Lao; Howard B Cottam; Dennis A Carson; Maripat Corr Journal: PLoS One Date: 2012-09-28 Impact factor: 3.240
Authors: Georg Stary; Christine Bangert; Martina Tauber; Robert Strohal; Tamara Kopp; Georg Stingl Journal: J Exp Med Date: 2007-05-29 Impact factor: 14.307